Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT04081220

Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

An Investigator Initiated Phase 2 Trial of the LSD1 Inhibitor IMG-7289 in Essential Thrombocythemia (CTMS# 19-0078)

Status
Active Not Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
9 (actual)
Sponsor
The University of Texas Health Science Center at San Antonio · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.

Conditions

Interventions

TypeNameDescription
DRUGIMG-7289Single starting dose with individualized dose titrations throughout

Timeline

Start date
2020-04-09
Primary completion
2023-12-20
Completion
2026-12-20
First posted
2019-09-09
Last updated
2025-09-10
Results posted
2025-05-20

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04081220. Inclusion in this directory is not an endorsement.

Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 (NCT04081220) · Clinical Trials Directory